Conflict of interest & Avandia articles
Money doesn’t talk, it swears. More on Avandia, the drug which keeps on giving topics for investigation.
Sorry, folks, as long as the research is controlled by those who will profit, it will be a serious problem. It is just like the illegal drug trade, as long as the profits are extremely lucrative, dirty deeds will be frequent and research will become increasingly more tainted.
In February, The New York Times described confidential F.D.A. reports recommending that Avandia be removed from the market.
To explore possible links between authors’ financial interests and opinions, researchers reviewed 202 articles by 180 authors who wrote about Avandia and the risk of heart attack. Then they had independent reviewers with no conflicts of interest grade each article as favorable, neutral or unfavorable, based on the authors’ positions on an association between Avandia and heart attacks and on their recommendations for continuing or ending its use. The study was published online on March 18 in the journal BMJ.
Often, authors with favorable opinions of the drug were paid both by Avandia’s maker, GlaxoSmithKline, and by its competitors. Of those who offered favorable views, 87 percent had potential conflicts with Glaxo. Among authors who had unfavorable opinions, only 20 percent had received money from Glaxo…
more from the NY Times